drugset / Trial / NCT06351150
Efficacy and Safety of Angiotensin II Injection Versus Placebo in Patients With Refractory Distributed Shock
RandomizedParallel-groupQuadruple-blindTreatment
Summary
A randomized, double-blind, placebo-controlled study on the treatment of refractory distributed shock with angiotensin II injection, with a random ratio of 1:1. Assuming a success rate of 25% for the main therapeutic endpoint in the control group and 50% for the experimental group, a total of 214 subjects will be enrolled, including 107 in the experimental group and 107 in the control group.
Timeline
- Start
- 2024-07-23
- Primary completion
- 2027-06
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Angiotensin II | Peptide | 1.25 unknown | Other |
| Subject | Angiotensin II | Peptide | 160 unknown | Other |
Indications
No indication recorded.